Clinical Trial Update: Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression [Phase 2]

View source ↗

Summary

Phase 2 trial update of ASC22 (anti-PD-L1 antibody) in combination with chidamide for HIV-infected patients with suppressed viral load.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• ASC22 (anti-PD-L1 monoclonal antibody)
• Chidamide (chidamide)

Snippet

Sponsor: Shanghai Public Health Clinical Center | Conditions: HIV Infections | Phase 2 | Status: UNKNOWN